Organogenesis (NASDAQ:ORGO) Trading Up 11.8% – Here’s What Happened

Organogenesis (NASDAQ:ORGO) rose 11.8% during mid-day trading on Monday . The stock traded as high as $6.40 and last traded at $6.2940. Approximately 2,166,456 shares changed hands during trading, an increase of 52% from the average daily volume of 1,423,518 shares. The stock had previously closed at $5.63.

Analyst Upgrades and Downgrades

ORGO has been the topic of several research reports. Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Cantor Fitzgerald increased their price objective on Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Organogenesis in a report on Wednesday, October 8th. Finally, BTIG Research reiterated a “buy” rating and issued a $7.00 price target on shares of Organogenesis in a research note on Friday, September 26th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $7.33.

Organogenesis Trading Up 16.2%

The company has a market cap of $829.66 million, a P/E ratio of -54.50 and a beta of 1.68. The stock’s 50 day moving average is $4.43 and its 200-day moving average is $4.19. The company has a current ratio of 3.32, a quick ratio of 2.88 and a debt-to-equity ratio of 0.01.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. The business had revenue of $150.86 million during the quarter, compared to analyst estimates of $134.10 million. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. Organogenesis has set its FY 2025 guidance at EPS. Research analysts anticipate that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Institutional Trading of Organogenesis

A number of institutional investors and hedge funds have recently modified their holdings of ORGO. State of Alaska Department of Revenue bought a new position in shares of Organogenesis during the third quarter valued at $25,000. Farther Finance Advisors LLC purchased a new position in Organogenesis in the 2nd quarter worth about $35,000. Ground Swell Capital LLC bought a new position in Organogenesis during the 2nd quarter valued at about $39,000. Walleye Capital LLC purchased a new stake in shares of Organogenesis during the 2nd quarter valued at about $45,000. Finally, Regent Peak Wealth Advisors LLC bought a new stake in shares of Organogenesis in the third quarter worth approximately $51,000. Institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.